Sessa C, Viganò L, Grasselli G, Trigo J, Marimon I, Lladò A, Locatelli A, Ielmini N, Marsoni S, Gianni L

Phase I clinical and pharmacological evaluation of the multi-tyrosine kinase inhibitor SU006668 by chronic oral dosing.

Eur J Cancer 2006; 171-8. doi: 10.1016/j.ejca.2005.09.033

Sessa C, Cresta S, Cerny T, Baselga J, Rota Caremoli E, Malossi A, Hess D, Trigo J, Zucchetti M, D'Incalci M, Zaniboni A, Capri G, Gatti B, Carminati P, Zanna C, Marsoni S, Gianni L

Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors.

Ann Oncol 2007; 561-8. doi: 10.1093/annonc/mdl418

Sessa C, Perotti A, Lladò A, Cresta S, Capri G, Voi M, Marsoni S, Corradino I, Gianni L

Phase I clinical study of the novel epothilone B analogue BMS-310705 given on a weekly schedule.

Ann Oncol 2007; 1548-53. doi: 10.1093/annonc/mdm198

Sessa C, Cresta S, Noberasco C, Capri G, Gallerani E, De Braud F, Zucchetti M, D'Incalci M, Locatelli A, Marsoni S, Corradino I, Minoia C, Zintl P, Gianni L

Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours.

Eur J Cancer 2009; 2116-22. doi: 10.1016/j.ejca.2009.04.002

Frapolli R, Zucchetti M, Sessa C, Marsoni S, Viganò L, Locatelli A, Rulli E, Compagnoni A, Bello E, Pisano C, Carminati P, D'Incalci M

Clinical pharmacokinetics of the new oral camptothecin gimatecan: the inter-patient variability is related to alpha1-acid glycoprotein plasma levels.

Eur J Cancer 2010; 505-16. doi: 10.1016/j.ejca.2009.11.006

Rojo F, Gracias E, Villena N, Cruz T, Corominas JM, Corradino I, Cedeño M, Campas C, Osorio M, Iznaga N, Bellosillo B, Rovira A, Marsoni S, Gascon P, Serrano S, Sessa C, Crombet T, Albanell J

Pharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: a SENDO Foundation study.

Clin Cancer Res 2010; 2474-82. doi: 10.1158/1078-0432.CCR-09-3042

Mello-Grand M, Singh V, Ghimenti C, Scatolini M, Regolo L, Grosso E, Zambelli A, Da Prada GA, Villani L, Fregoni V, Baiardi P, Marsoni S, Miller WR, Costa A, Chiorino G

Gene expression profiling and prediction of response to hormonal neoadjuvant treatment with anastrozole in surgically resectable breast cancer.

Breast Cancer Res Treat 2010; 399-411. doi: 10.1007/s10549-010-0887-y

Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, French AJ, Kabat B, Foster NR, Torri V, Ribic C, Grothey A, Moore M, Zaniboni A, Seitz JF, Sinicrope F, Gallinger S

Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer.

J Clin Oncol 2010; 3219-26. doi: 10.1200/JCO.2009.27.1825

Floriani I, Garassino MC, Broggini M, Veronese S, Marsoni S, Marabese M, Farina G, Scanni A

Role of cetuximab in the treatment of patients with NSCLC: are we throwing out the baby with the bath water?

J Clin Oncol 2010; e467; author reply e468. doi: 10.1200/JCO.2010.28.5973

Perotti A, Locatelli A, Sessa C, Hess D, Viganò L, Capri G, Maur M, Cerny T, Cresta S, Rojo F, Albanell J, Marsoni S, Corradino I, Berk L, Rivera VM, Haluska F, Gianni L

Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine.

J Clin Oncol 2010; 4554-61. doi: 10.1200/JCO.2009.27.5867

Sinicrope FA, Foster NR, Thibodeau SN, Marsoni S, Monges G, Labianca R, Kim GP, Yothers G, Allegra C, Moore MJ, Gallinger S, Sargent DJ

DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.

J Natl Cancer Inst 2011; 863-75. doi: 10.1093/jnci/djr153

Olmos D, A'hern RP, Marsoni S, Morales R, Gomez-Roca C, Verweij J, Voest EE, Schöffski P, Ang JE, Penel N, Schellens JH, Del Conte G, Brunetto AT, Evans TR, Wilson R, Gallerani E, Plummer R, Tabernero J, Soria JC, Kaye SB

Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors.

J Clin Oncol 2012; 996-1004. doi: 10.1200/JCO.2010.34.5074

Migliardi G, Sassi F, Torti D, Galimi F, Zanella ER, Buscarino M, Ribero D, Muratore A, Massucco P, Pisacane A, Risio M, Capussotti L, Marsoni S, Di Nicolantonio F, Bardelli A, Comoglio PM, Trusolino L, Bertotti A

Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.

Clin Cancer Res 2012; 2515-25. doi: 10.1158/1078-0432.CCR-11-2683

Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C, Corà D, Di Nicolantonio F, Buscarino M, Petti C, Ribero D, Russolillo N, Muratore A, Massucco P, Pisacane A, Molinaro L, Valtorta E, Sartore-Bianchi A, Risio M, Capussotti L, Gambacorta M, Siena S, Medico E, Sapino A, Marsoni S, Comoglio PM, Bardelli A, Trusolino L

A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.

Cancer Discov 2011; 508-23. doi: 10.1158/2159-8290.CD-11-0109

Parma G, Mancari R, Del Conte G, Scambia G, Gadducci A, Hess D, Katsaros D, Sessa C, Rinaldi A, Bertoni F, Vitali A, Catapano CV, Marsoni S, van de Velde H, Colombo N

An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens.

Int J Gynecol Cancer 2012; 792-800. doi: 10.1097/IGC.0b013e318251051a

Mandalà M, Grosso F, Vitalini C, Corradino I, Sanfilippo R, Colombini S, Clerici M, Labianca R, De Pascale A, Marsoni S

Venous thromboembolism is a relevant and underestimated adverse event in cancer patients treated in phase I studies.

Br J Cancer 2012; 612-6. doi: 10.1038/bjc.2012.325

Ploquin A, Olmos D, Lacombe D, A'Hern R, Duhamel A, Twelves C, Marsoni S, Morales-Barrera R, Soria JC, Verweij J, Voest EE, Schöffski P, Schellens JH, Kramar A, Kristeleit RS, Arkenau HT, Kaye SB, Penel N

Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin.

Br J Cancer 2012; 1025-30. doi: 10.1038/bjc.2012.371

Gallerani E, Zucchetti M, Brunelli D, Marangon E, Noberasco C, Hess D, Delmonte A, Martinelli G, Böhm S, Driessen C, De Braud F, Marsoni S, Cereda R, Sala F, D'Incalci M, Sessa C

A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma.

Eur J Cancer 2013; 290-6. doi: 10.1016/j.ejca.2012.09.009

de Marinis F, Atmaca A, Tiseo M, Giuffreda L, Rossi A, Gebbia V, D'Antonio C, Dal Zotto L, Al-Batran SE, Marsoni S, Wolf M

A phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in pretreated patients with small-cell lung cancer.

J Thorac Oncol 2013; 1091-4. doi: 10.1097/JTO.0b013e318293d88c

Garassino MC, Martelli O, Broggini M, Farina G, Veronese S, Rulli E, Bianchi F, Bettini A, Longo F, Moscetti L, Tomirotti M, Marabese M, Ganzinelli M, Lauricella C, Labianca R, Floriani I, Giaccone G, Torri V, Scanni A, Marsoni S

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.

Lancet Oncol 2013; 981-8. doi: 10.1016/S1470-2045(13)70310-3

Cassier PA, Polivka V, Judson I, Soria JC, Penel N, Marsoni S, Verweij J, Schellens JH, Morales-Barrera R, Schöffski P, Voest EE, Gomez-Roca C, Evans TR, Plummer R, Gallerani E, Kaye SB, Olmos D

Outcome of patients with sarcoma and other mesenchymal tumours participating in phase I trials: a subset analysis of a European Phase I database.

Ann Oncol 2014; 1222-8. doi: 10.1093/annonc/mdu108

Moreno García V, Olmos D, Gomez-Roca C, Cassier PA, Morales-Barrera R, Del Conte G, Gallerani E, Brunetto AT, Schöffski P, Marsoni S, Schellens JH, Penel N, Voest E, Evans J, Plummer R, Wilson RH, Soria JC, Tabernero J, Verweij J, Kaye SB

Dose-response relationship in phase i clinical trials: a European Drug Development Network (EDDN) Collaboration Study.

Clin Cancer Res 2014; 5663-71. doi: 10.1158/1078-0432.CCR-14-0719

Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, Ponzetti A, Cremolini C, Amatu A, Lauricella C, Lamba S, Hobor S, Avallone A, Valtorta E, Rospo G, Medico E, Motta V, Antoniotti C, Tatangelo F, Bellosillo B, Veronese S, Budillon A, Montagut C, Racca P, Marsoni S, Falcone A, Corcoran RB, Di Nicolantonio F, Loupakis F, Siena S, Sartore-Bianchi A, Bardelli A

Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.

Nat Med 2015; 795-801. doi: 10.1038/nm.3870

Rulli E, Marabese M, Torri V, Farina G, Veronese S, Bettini A, Longo F, Moscetti L, Ganzinelli M, Lauricella C, Copreni E, Labianca R, Martelli O, Marsoni S, Broggini M, Garassino MC

Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial.

Ann Oncol 2015; 2079-84. doi: 10.1093/annonc/mdv318

Marabese M, Ganzinelli M, Garassino MC, Shepherd FA, Piva S, Caiola E, Macerelli M, Bettini A, Lauricella C, Floriani I, Farina G, Longo F, Bonomi L, Fabbri MA, Veronese S, Marsoni S, Broggini M, Rulli E

KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy.

Oncotarget 2015; 34014-22. doi: 10.18632/oncotarget.5607

Bertotti A, Papp E, Jones S, Adleff V, Anagnostou V, Lupo B, Sausen M, Phallen J, Hruban CA, Tokheim C, Niknafs N, Nesselbush M, Lytle K, Sassi F, Cottino F, Migliardi G, Zanella ER, Ribero D, Russolillo N, Mellano A, Muratore A, Paraluppi G, Salizzoni M, Marsoni S, Kragh M, Lantto J, Cassingena A, Li QK, Karchin R, Scharpf R, Sartore-Bianchi A, Siena S, Diaz LA, Trusolino L, Velculescu VE

The genomic landscape of response to EGFR blockade in colorectal cancer.

Nature 2015; 263-7. doi: 10.1038/nature14969

Valtorta E, Martino C, Sartore-Bianchi A, Penaullt-Llorca F, Viale G, Risio M, Rugge M, Grigioni W, Bencardino K, Lonardi S, Zagonel V, Leone F, Noe J, Ciardiello F, Pinto C, Labianca R, Mosconi S, Graiff C, Aprile G, Frau B, Garufi C, Loupakis F, Racca P, Tonini G, Lauricella C, Veronese S, Truini M, Siena S, Marsoni S, Gambacorta M

Assessment of a HER2 scoring system for colorectal cancer: results from a validation study.

Mod Pathol 2015; 1481-91. doi: 10.1038/modpathol.2015.98

Sartore-Bianchi A, Trusolino L, Martino C, Bencardino K, Lonardi S, Bergamo F, Zagonel V, Leone F, Depetris I, Martinelli E, Troiani T, Ciardiello F, Racca P, Bertotti A, Siravegna G, Torri V, Amatu A, Ghezzi S, Marrapese G, Palmeri L, Valtorta E, Cassingena A, Lauricella C, Vanzulli A, Regge D, Veronese S, Comoglio PM, Bardelli A, Marsoni S, Siena S

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.

Lancet Oncol 2016; 738-746. doi: 10.1016/S1470-2045(16)00150-9

Apicella M, Migliore C, Capelôa T, Menegon S, Cargnelutti M, Degiuli M, Sapino A, Sottile A, Sarotto I, Casorzo L, Cassoni P, De Simone M, Comoglio PM, Marsoni S, Corso S, Giordano S

Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort.

Oncogene 2017; 1200-1210. doi: 10.1038/onc.2016.283

Germano G, Lamba S, Rospo G, Barault L, Magrì A, Maione F, Russo M, Crisafulli G, Bartolini A, Lerda G, Siravegna G, Mussolin B, Frapolli R, Montone M, Morano F, de Braud F, Amirouchene-Angelozzi N, Marsoni S, D'Incalci M, Orlandi A, Giraudo E, Sartore-Bianchi A, Siena S, Pietrantonio F, Di Nicolantonio F, Bardelli A

Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth.

Nature 2017; 116-120. doi: 10.1038/nature24673

Martinelli E, Troiani T, Sforza V, Martini G, Cardone C, Vitiello PP, Ciardiello D, Rachiglio AM, Normanno N, Sartore-Bianchi A, Marsoni S, Bardelli A, Siena S, Ciardiello F

Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case.

ESMO Open 2018; e000299. doi: 10.1136/esmoopen-2017-000299

Siena S, Sartore-Bianchi A, Marsoni S, Hurwitz HI, McCall SJ, Penault-Llorca F, Srock S, Bardelli A, Trusolino L

Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer.

Ann Oncol 2018; 1108-1119. doi: 10.1093/annonc/mdy100

Siravegna G, Lazzari L, Crisafulli G, Sartore-Bianchi A, Mussolin B, Cassingena A, Martino C, Lanman RB, Nagy RJ, Fairclough S, Rospo G, Corti G, Bartolini A, Arcella P, Montone M, Lodi F, Lorenzato A, Vanzati A, Valtorta E, Cappello G, Bertotti A, Lonardi S, Zagonel V, Leone F, Russo M, Balsamo A, Truini M, Di Nicolantonio F, Amatu A, Bonazzina E, Ghezzi S, Regge D, Vanzulli A, Trusolino L, Siena S, Marsoni S, Bardelli A

Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer.

Cancer Cell 2018; 148-162.e7. doi: 10.1016/j.ccell.2018.06.004

Lo Russo G, Moro M, Sommariva M, Cancila V, Boeri M, Centonze G, Ferro S, Ganzinelli M, Gasparini P, Huber V, Milione M, Porcu L, Proto C, Pruneri G, Signorelli D, Sangaletti S, Sfondrini L, Storti C, Tassi E, Bardelli A, Marsoni S, Torri V, Tripodo C, Colombo MP, Anichini A, Rivoltini L, Balsari A, Sozzi G, Garassino MC

Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade.

Clin Cancer Res 2019; 989-999. doi: 10.1158/1078-0432.CCR-18-1390

Mauri G, Pizzutilo EG, Amatu A, Bencardino K, Palmeri L, Bonazzina EF, Tosi F, Carlo Stella G, Burrafato G, Scaglione F, Marsoni S, Siravegna G, Bardelli A, Siena S, Sartore-Bianchi A

Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies.

Cancer Treat Rev 2019; 41-53. doi: 10.1016/j.ctrv.2018.12.006

Siravegna G, Sartore-Bianchi A, Nagy RJ, Raghav K, Odegaard JI, Lanman RB, Trusolino L, Marsoni S, Siena S, Bardelli A

Plasma HER2 (ERBB2) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer.

Clin Cancer Res 2019; 3046-3053. doi: 10.1158/1078-0432.CCR-18-3389

Sartore-Bianchi A, Amatu A, Porcu L, Ghezzi S, Lonardi S, Leone F, Bergamo F, Fenocchio E, Martinelli E, Borelli B, Tosi F, Racca P, Valtorta E, Bonoldi E, Martino C, Vaghi C, Marrapese G, Ciardiello F, Zagonel V, Bardelli A, Trusolino L, Torri V, Marsoni S, Siena S

HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer.

Oncologist 2019; 1395-1402. doi: 10.1634/theoncologist.2018-0785

Corti G, Bartolini A, Crisafulli G, Novara L, Rospo G, Montone M, Negrino C, Mussolin B, Buscarino M, Isella C, Barault L, Siravegna G, Siena S, Marsoni S, Di Nicolantonio F, Medico E, Bardelli A

A Genomic Analysis Workflow for Colorectal Cancer Precision Oncology.

Clin Colorectal Cancer 2019; 91-101.e3. doi: 10.1016/j.clcc.2019.02.008

Amatu A, Schirripa M, Tosi F, Lonardi S, Bencardino K, Bonazzina E, Palmeri L, Patanè DA, Pizzutilo EG, Mussolin B, Bergamo F, Alberti G, Intini R, Procaccio L, Arese M, Marsoni S, Nichelatti M, Zagonel V, Siena S, Bardelli A, Loupakis F, Di Nicolantonio F, Sartore-Bianchi A, Barault L

High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib.

Front Oncol 2019; 622. doi: 10.3389/fonc.2019.00622

Siravegna G, Mussolin B, Venesio T, Marsoni S, Seoane J, Dive C, Papadopoulos N, Kopetz S, Corcoran RB, Siu LL, Bardelli A

How liquid biopsies can change clinical practice in oncology.

Ann Oncol 2019; 1580-1590. doi: 10.1093/annonc/mdz227

%PLACEHOLDER%